| Literature DB >> 35056664 |
Elshaymaa I Elmongy1,2, Walaa A Negm3, Engy Elekhnawy4, Thanaa A El-Masry5, Nashwah G M Attallah1,6, Najla Altwaijry1, Gaber El-Saber Batiha7, Suzy A El-Sherbeni3.
Abstract
Monterey cypress (Cupressus macrocarpa) is a decorative plant; however, it possesses various pharmacological activities. Therefore, we explored the phytochemical profile of C. macrocarpa root methanol extract (CRME) for the first time. Moreover, we investigated its antidiarrheal (in vivo), antibacterial, and antibiofilm (in vitro) activities against Salmonella enterica clinical isolates. The LC-ESI-MS/MS analysis of CRME detected the presence of 39 compounds, besides isolation of 2,3,2″,3″-tetrahydro-4'-O-methyl amentoflavone, amentoflavone, and dihydrokaempferol-3-O-α-l-rhamnoside for the first time. Dihydrokaempferol-3-O-α-l-rhamnoside presented the highest antimicrobial activity and the range of values of MICs against S. enterica isolates was from 64 to 256 µg/mL. The antidiarrheal activity of CRME was investigated by induction of diarrhea using castor oil, and exhibited a significant reduction in diarrhea and defecation frequency at all doses, enteropooling (at 400 mg/kg), and gastrointestinal motility (at 200, 400 mg/kg) in mice. The antidiarrheal index of CRME increased in a dose-dependent manner. The effect of CRME on various membrane characters of S. enterica was studied after typing the isolates by ERIC-PCR. Its impact on efflux and its antibiofilm activity were inspected. The biofilm morphology was observed using light and scanning electron microscopes. The effect on efflux activity and biofilm formation was further elucidated using qRT-PCR. A significant increase in inner and outer membrane permeability and a significant decrease in integrity and depolarization (using flow cytometry) were detected with variable percentages. Furthermore, a significant reduction in efflux and biofilm formation was observed. Therefore, CRME could be a promising source for treatment of gastrointestinal tract diseases.Entities:
Keywords: Cupressus macrocarpa; ERIC-PCR; LC-MS/MS; flow cytometry; permeability; qRT-PCR
Mesh:
Substances:
Year: 2022 PMID: 35056664 PMCID: PMC8780600 DOI: 10.3390/molecules27020346
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Metabolite Profiling of CRME identified by LC-MS/MS in negative mode.
| No | Assignment | RT | (M–H)−
| Formulas | Fragments or MS2 |
|---|---|---|---|---|---|
| 1 | D-(-)-Quinic acid | 1.234 | 191.056 | C7H12O6 | 127.039, 171.030, 191.053 |
| 2 | (-)-Shikimic acid | 1.235 | 173.0456 | C7H10O5 | 129.053, 137.021, 155.039, 173.043 |
| 3 | Maleic acid | 1.237 | 115.0018 | C4H4O4 | 71.018, 114.999 |
| 4 | Citraconic acid | 1.299 | 129.0532 | C5H6O4 | 29.050, 85.001 |
| 5 | Procyanidin B2 | 4.592 | 577.1344 | C30H26O12 | 289.021, 425.126, 577.134 |
| 6 | Urocanic acid | 4.745 | 137.0244 | C6H6N2O2 | 137.024 |
| 7 | (-)-Epicatechin | 4.865 | 289.0729 | C15H14O6 | 245.080, 289.072 |
| 8 | Neohesperidin dihydrochalcone | 5.273 | 611.1586 | C28H36O15 | 543.161, 548.867, 611.165 |
| 9 | Dihydrokaempferol-3- | 5.355 | 433.1909 | C21H22O10 | 179.059, 288.312, 342.957, 434.189 |
| 10 | Apigenin-7- | 5.677 | 577.1384 | C27H30O14 | 269.043, 425.081, 532.910, 577.118 |
| 11 | Procyanidin C1 | 5.677 | 865.1961 | C45H38O18 | 289.201, 465.301, 865.194 |
| 12 | Procyanidin B1 | 6.034 | 577.1349 | C30H26O12 | 289.231, 425.102, 577.125 |
| 13 | Naringenin-7- | 6.209 | 433.1129 | C21H22O10 | 271.065, 433.102, 433.196 |
| 14 | Amentoflavone | 6.221 | 537.194 | C30H18O10 | 375.152, 399.210, 443.012, 537.189 |
| 15 | 6.482 | 405.1201 | C20H22O9 | 243.067, 405.124 | |
| 16 | Isorhamnetin-3- | 6.894 | 623.1995 | C28H32O16 | 315. 211, 577.199, 623.171, 623.192 |
| 17 | Luteolin-7- | 6.982 | 447.0892 | C21H20O11 | 285.035, 402.878, 447.084 |
| 18 | Quercetin-3-D-xyloside | 7.060 | 433.1666 | C20H18O11 | 301.028, 326.927, 364.901, 433.164 |
| 19 | 5-Methoxysalicylic acid | 7.061 | 167.0348 | C8H8O4 | 152.010, 167.034 |
| 20 | Isorhamnetin-3- | 7.234 | 477.1055 | C22H22O12 | 315.325, 454.144, 477.109 |
| 21 | Ferulic acid | 7.402 | 193.0874 | C10H10O4 | 178.066, 193.085 |
| 22 | Tetrahydro-4′- | 7.668 | 555.440 | C31H24O10 | 541.022, 555.401 |
| 23 | Apigenin-7- | 7.805 | 431.0969 | C21H20O10 | 269.042, 430.886, 431.103 |
| 24 | Acacetin-7- | 7.855 | 591.1512 | C28H32O14 | 283.0124, 392.898, |
| 25 | Baicalein-7- | 7.994 | 445.1177 | C21H18O11 | 112.987, 163.079, 269.353, 445.109 |
| 26 | Kaempferol-3-glucuronide | 8.006 | 461.1081 | C21H18O12 | 285.331, 324.911, 392.897, 461.103 |
| 27 | Quercetin | 9.627 | 301.0349 | C15H10O7 | 255.101, 301.031 |
| 28 | Naringenin | 10.183 | 271.0601 | C15H12O5 | 93.040, 151.007, 271.057 |
| 29 | Sinapyl aldehyde | 11.077 | 207.0636 | C11H12O4 | 192.0412, 207.065 |
| 30 | 3,3′,4′,5,7-pentahydroxyflavan | 12.067 | 289.1812 | C15H14O6 | 271.159, 289.180 |
| 31 | 3′-methoxy-4′,5,7-trihydroxyflavonol (isorhamnetin) | 13.426 | 315.1947 | C16H12O7 | 227.109, 283.168, 315.195 |
| 32 | Hesperetin | 16.591 | 301.1769 | C16H14O6 | 301.178 |
| 33 | Apigenin | 16.725 | 269.1541 | C15H10O5 | 269.157 |
| 34 | Acacetin | 18.035 | 283.1747 | C16H12O5 | 268.153, 283.162 |
| 35 | Esculin | 18.257 | 339.1972 | C15H16O9 | 295.205, 303.902, 339.191 |
| 36 | Luteolin | 18.330 | 285.1844 | C15H10O6 | 269.158, 285.183 |
| 37 | 3,5,7-trihydroxy-4′-methoxyflavone | 20.352 | 299.2003 | C16H12O6 | 231.101, 283.155, 299.199 |
| 38 | Kaempferol-7-neohesperidoside | 21.203 | 593.1549 | C27H30O15 | 285.092, 389.172, 547.337, 593.131 |
| 39 | Glycyrrhizate (glycyrrhizin) | 26.874 | 821.3727 | C42H62O16 | 685.426, 775.427, 821.3 |
Figure 1Chemical structures of the isolated compounds from CRME.
Figure 2Dendrogram showing the degree of relatedness of S. enterica isolates as determined by ERIC-PCR fingerprinting.
Figure 3A chart showing the increase in the release of the material absorbing at 260 nm (indicating a decrease in the membrane integrity) from a representative S. enterica isolate after treatment with CRME (32 µg/mL).
Figure 4A chart showing the increase in the inner membrane permeability of a representative S. enterica isolate after treatment with CRME was determined by measuring the ONP absorbance with time.
Figure 5A chart showing the increase in the outer membrane permeability of a representative S. enterica isolate after treatment with CRME was detected by determining the fluorescence of NPN against time.
Figure 6A representative flow cytometric chart (dot plot) showing the fluorescent gap (a) before (95.7%) and (b) after (22.8%) treatment with CRME measured by FACS verse flow cytometer.
The change in efflux activity using the cartwheel method after treatment with CRME.
| Before Treatment | After Treatment | ||
|---|---|---|---|
| Minimum Conc. of EtBr (mg/L) | Efflux Activity * | Minimum Conc. of EtBr (mg/L) | Efflux Activity * |
| ≤0.5 (3) | -(N) | ≤0.5 (6) | -(N) |
| 1 (1) | +(I) | 1 (9) | +(I) |
| 1.5 (1) | +(I) | 1.5 (2) | +(I) |
| 2 (2) | +(I) | 2 (1) | +(I) |
| 2.5 (13) | ++(P) | 2 (2) | ++(P) |
* Classification of efflux activity into (N) Negative efflux activity; (I) Intermediate efflux activity; and (P) Positive efflux activity.
Figure 7Crystal violet assay for evaluation of the antibiofilm efficiency of CRME against S. enterica isolates showing a significant reduction (p < 0.05) in biofilm formation in 8 isolates (S1, S2, S4, S6, S8, S9, S11, and S13).
Figure 8A representative example of the decrease in biofilm formation by S. enterica isolates (a,b) viewed by the light microscope, and (c,d) viewed by the scanning electron microscope before (a,c) and after (b,d) treatment with CRME.
The relative expression of the genes encoding the efflux pump activity in S. enterica isolates after treatment with CRME.
| Isolate Code | Relative Gene Expression * | |||
|---|---|---|---|---|
| S1 |
|
| 1.1 ± 0.3 | 1.3 ± 0.2 |
| S2 | 1.3 ± 0.1 |
| 1.5 ± 0.3 | 1.0 ± 0.7 |
| S3 | 1.4 ± 0.0 |
| 1.7 ± 0.1 | 1.8 ± 0.2 |
| S5 |
| 1.1 ± 0.2 | 1.0 ± 0.4 | 1.1 ± 0.2 |
| S6 | 1.3 ± 0.2 |
| 1.2 ± 0.8 | 1.6 ± 0.2 |
| S7 |
| 1.0 ± 2.0 | 1.7 ± 0.2 | 1.5 ± 0.4 |
| S8 |
|
| 1.4 ± 0.9 | 1.4 ± 0.3 |
| S9 |
|
| 1.3 ± 0.0 | 0.9 ± 0.2 |
| S15 | 0.9 ± 0.1 |
| 1.2 ± 0.0 | 1.6 ± 0.2 |
| S19 |
|
| 1.6 ± 0.7 | 1.7 ± 0.2 |
| S20 |
| 1.6 ± 0.2 | 1.3 ± 0.1 | 1.2 ± 0.0 |
* The bolded values refer to the decrease in the gene expression ≥ 2-fold.
The relative expression (mean ± SD) of the tested genes related to biofilm formation in S. enterica isolates after treatment with CRME.
| Isolate Code | Relative Gene Expression | Isolate Code |
|---|---|---|
| S1 |
|
|
| S2 |
|
|
| S4 | 1.5 ± 0.3 |
|
| S6 |
| 1.2 ± 0.1 |
| S8 |
|
|
| S9 | 0.9 ± 0.2 |
|
| S11 |
| 1.8 ± 0.1 |
| S13 |
|
|
Antidiarrheal effect of CRME (results expressed as mean ± SD).
| Treatment | The Onset of Diarrhea (min) | No. of Dry Feces | No. of Wet Feces | Weight of Dry Feces (g) | Weight of Wet Feces (g) | % Defecation Inhibition |
|---|---|---|---|---|---|---|
| Control | 18.17 ± 1.5 | 11 ± 1.6 | 7.3 ± 1.2 | 1.8 ± 0.2 | 1.6 ± 0.0 | - |
| Loperamide | 100.33 ± 1.2 | 4 ± 0.8 | 1.7 ± 0.5 | 0.19 ± 0.0 | 0.1 ± 0.0 | 91.5 |
| CRME (100 mg/kg) | 68.5 ± 2.4 | 7 ± 0.8 | 3.7 ± 0.9 | 0.29 ± 0.0 | 0.19 ± 0.0 | 85.9 |
| CRME (200 mg/kg) | 87.6 ± 3.0 | 3.4 ± 0.5 | 2.4 ± 0.5 | 0.27 ± 0.0 | 0.14 ± 0.0 | 88 |
| CRME (400 mg/kg) | 108.5 ± 2.2 | 2.7 ± 0.5 | 1.7 ± 0.5 | 0.13 ± 0.0 | 0.09 ± 0.0 | 93.5 |
Impact of CRME on the castor oil-induced enteropooling in mice.
| Treatment | MVSIC * (mL) | % Inhibition in MVSIC | MWSIC ** (g) | % Inhibition in MWSIC |
|---|---|---|---|---|
| Control | 0.71 ± 0.00 | - | 0.78 ± 0.00 | - |
| Loperamide | 0.23 ± 0.02 | 67.6 | 0.18 ± 0.01 | 77 |
| CRME | 0.68 ± 0.00 | 4.23 | 0.71 ± 0.00 | 8.97 |
| CRME | 0.61 ± 0.00 | 14.08 | 0.7± | 10.26 |
| CRME | 0.18±0.00 | 74.6 | 0.17± | 78.2 |
* MVSIC: mean volume of the small intestinal content. ** MWSIC: mean weight of the small intestinal content. A significant reduction was caused by CRME in the MVSIC and MWSIC at the dose of 400 mg/kg b.w. compared to the control.
Impact of CRME on the intestinal transit of charcoal in mice.
| Treatment | Distance Traveled by Charcoal (cm) | Length of the Small Intestine (cm) | Peristalsis Index | % of Inhibition |
|---|---|---|---|---|
| Control | 41 ± 0.07 | 50.2 ± 0.17 | 81.67 | - |
| Loperamide | 10.4 ± 0.22 | 51.3 ± 0.25 | 20.27 | 74.63 |
| CRME | 37.37 ± 0.12 | 53.3 ± 0.21 | 70.11 | 8.85 |
| CRME | 14.37 ± 0.26 | 52.4 ± 0.33 | 27.42 | 64.95 |
| CRME | 8.1 ± 0.08 | 53.4 ± 0.22 | 15.16 | 80.24 |
The in vivo antidiarrheal index of CRME.
| Treatment | Delay in Defecation | Gut Meal Travel | Purging | Antidiarrheal |
|---|---|---|---|---|
| Control | - | - | - | - |
| Loperamide | 452.17 | 74.63 | 91.5 | 145.62 |
| CRME | 276.99 | 8.85 | 85.9 | 59.5 |
| CRME | 382.11 | 64.95 | 88 | 129.74 |
| CRME | 497.14 | 80.24 | 93.5 | 155.08 |